Search

Displaying results 4351 - 4360 of 7186 in total
  1. Drug

    GZ-389988

    go.drugbank.com/drugs/DB16056
    Investigational

    GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients

  2. Drug

    Fluphenazine

    go.drugbank.com/drugs/DB00623
    Approved

    Its properties and uses are generally similar to those of chlorpromazine.

  3. Drug

    Benzimate

    go.drugbank.com/drugs/DB05170
    Experimental

    Benzimate is the lead compound selected from a series of compounds known as benzimidazoles. … It is currently under investigation by AmpliMed and is in phase I of clinical trial.

  4. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … [A264688] Aberrant KMT2A is associated with the upregulation of leukemogenic transcription pathways, notably those involving _HOXA_ genes and their co-factor _MEIS1_.

    Synonyms: Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-
  5. Drug

    Nandrolone decanoate

    go.drugbank.com/drugs/DB08804
    ApprovedIllicitInvestigational

    L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic effect compared to

  6. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

  7. Drug

    Phensuximide

    go.drugbank.com/drugs/DB00832
    Approved

    The frequency of attacks is reduced by depression of nerve transmission in the motor cortex.

  8. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors

  9. Drug

    MCC

    go.drugbank.com/drugs/DB05282
    Investigational

    Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria. … MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension.

  10. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.